Business Context and Reporting Period
This Form 8-K filing by Bionano Genomics, Inc. (BNGO) reports a corporate event dated August 13, 2020. The Company, an emerging growth company incorporated in Delaware, entered into an At Market Issuance Sales Agreement to facilitate the potential sale of its common stock.
Key Financial Metrics
This filing does not contain periodic financial statements (e.g., revenue, profit, cash flow, or debt levels). The only financial figures disclosed relate to the terms of the new sales agreement:
- Maximum Offering Size: Up to $40.0 million in common stock.
- Commission Fee: Up to 3.0% of aggregate gross proceeds.
- Legal Reimbursement Cap: Up to $50,000 upon execution, plus up to $3,000 per calendar quarter for ongoing disbursements.
Material Changes
The material change reported is the execution of the Sales Agreement with Ladenburg Thalmann & Co. Inc. as the sales agent. This agreement allows the Company to sell shares through "at-the-market" offerings. The Company is not obligated to sell any shares, and sales are subject to the effectiveness of a Registration Statement on Form S-3 filed on the same date.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Company's intent to access capital markets flexibly but notes that the Company retains full discretion on the timing and volume of any sales.
Risks and Contingencies:
- Termination: The agreement may be terminated by either party with 10 days' prior notice.
- Material Adverse Effect: Ladenburg may terminate the agreement if a material adverse effect occurs on the Company's business or financial position.
- Regulatory Condition: Sales cannot commence until the SEC declares the Registration Statement effective.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement filed on August 13, 2020.
- Monitor future filings for actual share issuances and proceeds generated under the $40.0 million agreement.
- Review the Company's current cash position and burn rate to assess the necessity of this capital raise.
- Check for any subsequent 8-K filings regarding the termination of the Sales Agreement.